NEPHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
NEPHROS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$3.68+0.03 (+0.82%)
Close on Oct 19, 2026
- Market cap
- $40.89M
- P/E (TTM)
- 23.0
- Dividend yield
- –
NEPHROS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $19.96M | $18.57M | $18.23M | $17.46M | $16.34M | $15.24M | $14.04M | $13.38M | $13.63M | $13.95M | $14.11M | $13.45M | 96.3% | +22.2% |
| Royalty and Other Revenues [Member] | – | – | – | – | – | $282.00K | $127.00K | $162.00K | $145.00K | $109.00K | $128.00K | $88.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Nephros's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.